Osama Bin Laden's killer advocates for ibogaine therapy

Osama bin Laden’s killer advocates for ibogaine therapy

A former United States Navy SEAL credited with taking out Osama bin Laden in Pakistan 14 years ago has been advocating for ibogaine therapy.

In an interview with conservative political commentator Tucker Carlson last week, Robert O’Neill said the psychedelic drug was the only viable cure for his mental health demons. He has travelled to Mexico to undergo legal psychedelic therapy sessions with the psychoactive therapeutic and will soon be returning for additional ...

Continue Reading →
Gilgamesh's psychedelic drug demonstrates remarkable efficacy for treating depression

Gilgamesh’s psychedelic drug demonstrates exceptional efficacy for treating depression

Privately-held Gilgamesh Pharmaceuticals has reported immense success treating depression with its novel psychedelic compound.

On Tuesday, the company dropped data from a Phase 2a study showing that nearly all trial participants suffering from the mental health condition went into remission post-adminstration. Specifically, 70 per cent reported immense alleviation from their major depressive disorder (MDD) within two weeks and 94 per cent went into remission within 30 days.

GM-2505 gets administered via intravenous infusion with ...

Continue Reading →
Texas makes its mark on psychedelics sector with US$50M in ibogaine research funding

Texas makes its mark on psychedelics sector with US$50M in ibogaine research funding

Texas is making history by funding a major ibogaine research initiative with an unprecedented sum. As the United States continues to grapple with an increasing rate of mental health conditions, the need for efficacious new treatment modalities is immense.

This is particularly true among the American veterans community. Depression, PTSD, and substance use disorders resulting from those conditions are alarmingly prevalent. So is suicide, unfortunately.

On Thursday, a press release credited to the Texas ...

Continue Reading →
Psyence BioMed invests half a million into natural psychedelics operator PsyLabs

Psyence BioMed invests half a million into natural psychedelics operator PsyLabs

Toronto-based Psyence Biomedical Ltd (NASDAQ: PBM) just invested US$500,000 into the private South African drug developer PsyLabs. The capital injection follows Psyence taking an 11 per cent stake in the natural psychedelics company in September.

PsyLabs is federally licensed to produce psilocybin, psilocin, mescaline, DMT and ibogaine for international research partners at its facility in Cape Town. It has been in operation for four years. The extraction ...

Continue Reading →
UA-77446339-1